Tag Archive for: zilebesiran

The companies stated that their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

Alnylam Pharmaceuticals is already making progress on its July 2023 deal with Roche to co-develop and commercialize zilebesiran, the former’s investigational RNAi therapeutic. The Cambridge biotech reported positive topline Phase II results Thursday for its partnered gene-silencing therapy to treat hypertension. 

The trial data reinforces the potential for zilebesiran to offer “new possibilities in a field of medicine that has seen limited innovation in nearly 20 years,” said Simon Fox, program lead for the drug’s development.

Under the deal, Roche will make an upfront payment of $310 million in cash. Alnylam is also entitled to development, regulatory and sales milestones, with a potential contract value of up to $2.8 billion.